The Effects of Aldosterone Synthase Inhibition on Aldosterone and Cortisol in Patients With Hypertension: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Study
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
J Clin Hypertens (Greenwich). 2012; 14:580–587. © 2012 Wiley Periodicals, Inc. Blockade of the renin‐angiotensin‐aldosterone system (RAAS) is an established method to lower blood pressure in patients with hypertension. Aldosterone, the end product of the RAAS cascade, acts by increasing salt reabsorption in the kidney and catecholamine release from the adrenal medulla. Currently available aldosterone inhibitors have the disadvantage of increasing circulating aldosterone and thus may lead to aldosterone breakthrough. Aldosterone synthase inhibition (ASI) is a novel approach to suppressing the RAAS. Due to homology between the enzymes responsible for aldosterone synthesis (CYP11B2) and cortisol synthesis (CYP11B1), the blockade of aldosterone synthesis may also suppress cortisol release. The authors evaluated the effect of the novel ASI LCI699 on the cortisol response to adrenocorticotropic hormone (ACTH) stimulation in patients with hypertension in order to find the maximally tolerated dose (MTD) in this patient population. Among the 63 patients evaluated, there was a dose‐ and time‐dependent effect of LCI699 on both aldosterone and ACTH‐stimulated cortisol. Based on exposure‐response analysis, the MTD was estimated to be 1.30 mg once daily with a 90% prediction interval of 0.88 mg once daily to 1.81 mg once daily. No patients required intervention for adrenal insufficiency. LCI699 was well tolerated with no serious adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Cited by
Long-term space flight simulation reveals infradian rhythmicity in human Na(+) balance
Rakova, N., Jüttner, K., Dahlmann, A., Schröder, A., Linz, P., Kopp, C., Rauh, M., Goller, U., Beck, L., Agureev, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.11.013 · Cited by 328
“The enzymes responsible for aldosterone synthesis (CYP11B2) and cortisol synthesis (CYP11B1) are highly homologous, and investigators have considered the possibility that aldosterone synthesis blockade could also suppress cortisol release (Andersen et al., 2012).”
BackgroundNew approaches in the treatment of hypertension
Oparil, S., & Schmieder, R. E. (2015) · Circulation Research · doi:10.1161/circresaha.116.303603 · Cited by 276
Study of Aldosterone Synthase Inhibition as an Add‐On Therapy in Resistant Hypertension
Karns, A. D., Bral, J. M., Hartman, D., Peppard, T., & Schumacher, C. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12051 · Cited by 104
“Unfortunately, higher doses of LCI699 are unlikely to be tested due to concern over off-target effects on cortisol synthesis due to loss of steroidogenic target selectivity.(18,20,23) A potential explanation may be that non-aldosterone compounds, such as 11DOC and cortisol, play a larger role in activating MR irrespec…”
BackgroundSelf-citationAldosterone synthase inhibitors in cardiovascular and renal diseases
Namsolleck, P., & Unger, T. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft402 · Cited by 63
“The selectivity of the LCI699 with respect to the suppression of cortisol levels was studied in 63 patients with essential hypertension [39].”
Aldosterone Synthase Inhibition in Hypertension
Andersen, K. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0379-7 · Cited by 12
Self-citation
Metadata
- Authors
- Andersen, K., Hartman, D., Peppard, T., Hermann, D., Van Ess, P., Lefkowitz, M., & Trapani, A.
- Venue
- The Journal of Clinical Hypertension
- Publisher
- Wiley
- Published
- 2012-06-07
- Volume
- 14
- Issue
- 9
- Pages
- 580-587
- ISSN
- 1524-6175 (ISSN-L)
- 1751-7176
- OpenAlex
- W2145807241
- Cited by
- 68
- References
- 2
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effects of Aldosterone Synthase Inhibition on Aldosterone and Cortisol in Patients With Hypertension: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Study. https://app.cochat.ai/papers/10.1111/j.1751-7176.2012.00667.x
- The paper
- Andersen, K., Hartman, D., Peppard, T., Hermann, D., Van Ess, P., Lefkowitz, M., & Trapani, A. (2012). The Effects of Aldosterone Synthase Inhibition on Aldosterone and Cortisol in Patients With Hypertension: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Study. The Journal of Clinical Hypertension. https://doi.org/10.1111/j.1751-7176.2012.00667.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.